#Drug Discovery

OpenAI Unveils LifeSciBench

OpenAI's LifeSciBench is a new benchmark designed to test AI's real-world applicability in complex life science research, moving beyond basic question answering.

Zuckerberg & Chan on Open-Source Biology

Mark Zuckerberg and Priscilla Chan discuss Biohub's open-source AI initiative, aiming to accelerate biological discovery and protein design.

Claude's Corner: Confluence Labs, The Startup That Cracked ARC-AGI-2

Confluence Labs scored 97.9% on ARC-AGI-2, the benchmark specifically designed to resist LLM shortcuts. Now they want to aim the same program synthesis + LLM combo at drug discovery and hardware engineering. Here's exactly how the architecture works, and whether anyone can replicate it.

OpenAI Boosts AI for Drug Discovery

OpenAI's GPT-Rosalind receives major upgrades for life sciences, enhancing drug discovery and genomics with improved reasoning and workflow execution capabilities.

The Bitter Lesson: AI's Protein Problem

Alex Rives of Biohub explains how AI language models are learning the 'grammar' of protein biology, enabling the design of new proteins and therapeutics.

Claude's Corner: Mantis Biotech, The Digital Twin Factory Solving Medicine's Data Problem With Physics

Mantis Biotech (YC W26) builds human digital twins by fusing LLMs with physics simulation engines to generate scientifically credible synthetic biomedical training data. Deep technical breakdown and replicability analysis.

Gosset AI: Drug Discovery Precision Leap

Gosset AI platform outperforms frontier LLMs in niche drug discovery by 3.2x, demonstrating the power of curated data over generic web search for R&D.

BioMiner: Unlocking Drug Discovery Data

BioMiner, a novel multi-modal framework, automates protein-ligand bioactivity extraction, accelerating drug discovery and enabling identification of novel therapeutic candidates.

AI and Cancer: How Noetik.ai is Revolutionizing Drug Discovery

Ron Alfa of Noetik.ai discusses how AI is being used to understand patient biology and improve cancer drug discovery, moving beyond broad classifications to personalized treatments.

OpenAI Leaders Discuss Building AI for Life Sciences

OpenAI's Joy Jiao and Yunyun Wang discuss how AI is transforming life sciences, enabling new discoveries and accelerating research workflows.

OpenAI Unveils GPT-Rosalind for Science

OpenAI launches GPT-Rosalind, a specialized AI model designed to accelerate life sciences research and drug discovery workflows.

Helical AI Lab Secures $10M for Pharma Discovery

Helical raises $10M for its virtual AI lab, aiming to make in-silico drug discovery reproducible and scalable for pharmaceutical giants.

Databricks AI Speeds Drug Discovery

Databricks unveils AiChemy, a multi-agent AI system accelerating drug discovery by integrating diverse data sources and enabling autonomous research.

Tevogen Bio's AI Slashes Drug Discovery Time

Tevogen Bio drastically cut drug discovery timelines from months to 24 hours using AI and a Databricks Lakehouse platform, aiming for more affordable therapies.

TetraScience Unlocks Biopharma AI

TetraScience partners with Databricks to transform biopharma R&D by making lab data AI-ready, slashing development times and accelerating drug discovery.

XPRIZE Quantum Applications: Finalists Push Real-World Quantum

Generative Antibody Design Cracks 'Undruggable' Targets

Onepot AI Secures $13 Million to Revolutionize Chemical Synthesis for Drug Discovery

The AI-Driven Future of Biotech: Insights from Benchling's CEO

Lilly Blackwell Drug Discovery: A New Era

Tahoe-x1 single cell model scales AI for cancer drug discovery

Google's AI Tools Advance Cancer Fight

AI Cancer Breakthrough: Gemma Model Uncovers New Therapy

Salt AI Raises $10M to Advance Contextual AI in Life Sciences

Biotech's AI Infusion: A Tremendous Opportunity

Virtual Cells: Unlocking Biology's Latent Speed with AI

Enveda Secures $150M Series D, Achieves Unicorn Status

Treeline Biosciences Raises $200M, Initiates Clinical Trials

The company also initiated Phase 1 trials for three oncology programs, including a pan-KRAS inhibitor.

Tahoe Therapeutics Raises $30M for AI Human Cell Models

Tahoe Therapeutics secured $30 million in new funding. Amplify Partners led the round. This capital will fuel the creation of AI models of human cells to advance drug discovery.

Latvian Cellbox Labs Lands €3.3M for Organ-on-Chip Innovation

Latvian Cellbox Labs secured €3.3 million in non-dilutive funding. This capital, partly from the IPCEI “Tech4Cure” initiative, supports its organ-on-chip technology development. The investment aims to advance drug discovery and reduce reliance on animal testing.

Latvian Cellbox Labs Lands €3.3M for Organ-on-Chip Innovation

Riga-based Cellbox Labs secured €3.3 million in non-dilutive funding. This capital, partly from the Important Project of Common European Interest (IPCEI) “Te...

SNIPR Biome Secures €35M Series B for CRISPR Therapies

SNIPR Biome, a Danish biotech, secured €35 million in Series B funding. New investors Cystic Fibrosis Foundation and SPRIN-D joined the round, alongside existing backers. This capital will advance its microbial CRISPR-medicine development, including therapies for cystic fibrosis and antimicrobial resistance.

SNIPR Biome Secures €35M Series B for CRISPR Therapies

Copenhagen-based SNIPR Biome, a Danish biotech scale-up, secured €35 million in Series B funding.

AI's Amplifying Force in Scientific Discovery: The AlphaFold Breakthrough

Investors Eye Quantum as the Next AI Frontier

Vivodyne Secures $40 Million to Revolutionize Drug Discovery

John Snow Labs Acquires WiseCube to Refine and Safeguard Medical AI Models with Knowledge Graphs

PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

IAG Capital Partners Leads $24M in Generative AI Startup for Drug Discovery, DeepCure

9xchange and BenevolentAI Announce Strategic Partnership on Biopharma Asset Marketplace

DeepCure Closes $40 million Series A Funding Led by Morningside Ventures

Series A financing will catalyze growth and advance novel small molecule therapeutics pipeline across various disease indications. The funding will also be used to build an automated robotic wet lab to complete DeepCure’s vision of end-to-end AI drug discovery